Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Blood (2024) 144 (Supplement 1): 227.

https://doi.org/10.1182/blood-2024-194060

Published: 2024

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau

Blood (2024) 143 (20): 2029–2036.

https://doi.org/10.1182/blood.2023023597

Published: 2024

Includes: Supplemental data

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau

Blood (2023) 142 (Supplement 1): 207.

https://doi.org/10.1182/blood-2023-174044

Published: 2023

Journal Articles

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Blood (2023) 141 (11): 1308–1315.

https://doi.org/10.1182/blood.2022017863

Published: 2023

Includes: Supplemental data

Journal Articles

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Blood (2022) 140 (Supplement 1): 8996–8998.

https://doi.org/10.1182/blood-2022-159125

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Blood (2022) 139 (17): 2666–2672.

https://doi.org/10.1182/blood.2021014968

Published: 2022

Includes: Supplemental data

Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal

Blood (2021) 138 (Supplement 1): 464.

https://doi.org/10.1182/blood-2021-146040

Published: 2021

Journal Articles

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones

Blood (2021) 138 (Supplement 1): 77.

https://doi.org/10.1182/blood-2021-146869

Published: 2021

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Light Chain Escape in Multiple Myeloma

Thomas Dejoie, MD, Guillemette Fouquet, Cyrille Hulin, Murielle Roussel, Benjamin Hebraud, Lionel Karlin, MD, Brigitte Kolb, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Mourad Tiab, MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, Gérard Lepeu, MD, Marie Lorraine Chretien, MD, Denis Caillot, Jean Fontan, MD, Philippe Rodon, MD, Anna Schmitt, Laurent Voillat, MD, Sophie Cereja, MD, Brigitte Pegourie, MD, Frederique Kuhnowski, MD, Sophie Rigaudeau, MD, Olivier Decaux, MD, Catherine Humbrecht-Kraut, MD, Jamilé Frayfer, MD, Laurent Garderet, Damien Roos-Weil, MD, Jean Claude Eisenmann, MD, Veronique Dorvaux, MD, Eric G. Voog, MD, Claire Mathiot, MD, Jean-Paul Fermand, MD, Thierry Facon, Hervé Avet-Loiseau, MD PhD, Jean Luc Harousseau, MD, Philippe Moreau, Michel Attal, MD PhD, Xavier Leleu, MD PhD

Blood (2018) 132 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2018-99-112396

Published: 2018

Journal Articles

Time to Improve Bortezomib and Lenalidomide Lines of Therapy

Blood (2017) 130 (Supplement 1): 1853.

https://doi.org/10.1182/blood.V130.Suppl_1.1853.1853

Published: 2017

Journal Articles

Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France

Cyrille Hulin, MD, Margaret Macro, MD, Sophie Gourgou, Bertrand Arnulf, MD PhD, Florence Lachenal, Caroline Lenoir, Anne-Marie Stoppa, MD, Marie Lorraine Chretien, Laure Vincent, Aurore Perrot, MD, Philippe Moreau, MDPhD, Lionel Karlin, MD, Cécile Fohrer, Jean-Richard Eveilard, Jean Fontan, MD, Olivier Decaux

Blood (2017) 130 (Supplement 1): 1848.

https://doi.org/10.1182/blood.V130.Suppl_1.1848.1848

Published: 2017

Journal Articles

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Blood (2016) 128 (25): 2941–2948.

https://doi.org/10.1182/blood-2016-07-726778

Published: 2016

Journal Articles

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM

Blood (2016) 128 (22): 3569.

https://doi.org/10.1182/blood.V128.22.3569.3569

Published: 2016

Journal Articles

IFM2012-03

Blood (2016) 128 (22): 2128.

https://doi.org/10.1182/blood.V128.22.2128.2128

Published: 2016

Journal Articles

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Eileen Mary Boyle, MD MSc, Marie-Odile Petillon, MD, Charles Herbaux, MD, Johanna Mimouni, Xavier Leleu, Lionel Karlin, MD, Chantal Doyen, MD, Marc Wetterwald, MD PhD, Muriel Roussel, MD, Cyrille Hulin, Bruno Royer, MD, Margaret Macro, Philippe Moreau, Karel Fostier, MD, Mamoun Dib, Sabine Brechignac, MD, Caroline Bureau, Gerald Marit, MD, Adrian Tempescul, MD, Marie Lorraine Chretien, Charles Zarnitsky, Cecile Fohrer, MD, Aurore Perrot, MD, Lotfi Benboubker, MD PhD, Laurent Voillat, Jean Valere Malfuson, Clara Mariette, Mourad Tiab, Sophie Rigaudeau, Arnaud Jaccard, MD PhD, Anne-Marie Stoppa, Laure Vincent, Jean Claude Eisenmann, MD, Laurent Frenzel, Bertrand Arnulf, MD, Mohamad Mohty, MD PhD, Philippe Rodon, MD, Brigitte Kolb, Olivier Decaux, MD PhD, Pascal Godmer, David Beauvais, Benjamin Carpentier, Sarah Bonnet, MD, Thomas Longval, Mathieu Dewevre, Herve Avet-Loiseau, MD PhD, Michel Attal, Susanna Schraen, PharmD, Thierry Facon

Blood (2016) 128 (22): 2138.

https://doi.org/10.1182/blood.V128.22.2138.2138

Published: 2016

Journal Articles

Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group

Blood (2016) 128 (22): 4612.

https://doi.org/10.1182/blood.V128.22.4612.4612

Published: 2016

Journal Articles

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Blood (2015) 126 (25): 2713–2719.

https://doi.org/10.1182/blood-2015-06-650242

Published: 2015

Includes: Supplemental data

NARROW

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Light Chain Escape in Multiple Myeloma

Time to Improve Bortezomib and Lenalidomide Lines of Therapy

Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM

IFM2012-03

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only